Evidence map›Paper›PMID 28155079›Full record

ReviewMolecular imaging and biology2017

Fluorescence Imaging for Cancer Screening and Surveillance.

K E Tipirneni, E L Rosenthal, L S Moore, A D Haskins, N Udayakumar, A H Jani, W R Carroll, A B Morlandt, M Bogyo, J Rao and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 66 citations in OpenAlex.

  1. Emission-tunable aromatic thiadiazole derivatives based on triphenylimidazole with aggregation-induced emission activity and their application in osteosarcoma imaging.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. UrinaryCancers · 2023
    Article
  11. Intraoperative Tumor Detection Using Pafolacianine.International journal of molecular sciences · 2022
    Review
  12. Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China.European journal of nuclear medicine and molecular imaging · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Antibody-Targeted Imaging of Gastric Cancer.Molecules (Basel, Switzerland) · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

K E TipirneniDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
E L RosenthalDepartment of Otolaryngology, Stanford University, Stanford, CA, USA.
L S MooreDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA.
A D HaskinsDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA.
N UdayakumarDepartment of Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
A H JaniSchool of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
W R CarrollDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA.
A B MorlandtDepartment of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
M BogyoDepartment of Pathology, Stanford University, Stanford, CA, USA.
J RaoDepartment of Radiology, Stanford University, Stanford, CA, USA.
Jason M WarramDepartment of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, USA. mojack@uab.edu.
University of Alabama at Birmingham · USStanford University · US

Funding

National Institutes of Health T32CA091078
6 · The paper itself

Abstract

The advent of fluorescence imaging (FI) for cancer cell detection in the field of oncology is promising for both cancer screening and surgical resection. Particularly, FI in cancer screening and surveillance is actively being evaluated in many new clinical trials with over 30 listed on Clinical Trials.gov . While surgical resection forms the foundation of many oncologic treatments, early detection is the cornerstone for improving outcomes and reducing cancer-related morbidity and mortality. The applications of FI are twofold as it can be applied to high-risk patients in addition to those undergoing active surveillance. This technology has the promise of highlighting lesions not readily detected by conventional imaging or physical examination, allowing disease detection at an earlier stage of development. Additionally, there is a persistent need for innovative, cost-effective imaging modalities to ameliorate healthcare disparities and the global burden of cancer worldwide. In this review, we outline the current utility of FI for screening and detection in a range of cancer types.

Indexed as

Early Detection of CancerPopulation SurveillanceClinical Trials as TopicDiagnostic ImagingFluorescenceHumansNeoplasmsCancer screeningDiagnostic imagingEarly detection of cancerMolecular imagingNeoplasmsOptical imaging

Identifiers

PMID28155079
OpenAlexW2583699093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.